/ Print /

PHARMACY BEST PRACTICES

Value-based drug contracting shifts risk to manufacturersValue-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Why there’s an uptick in outcomes-based contractsOperational issues aside, outcomes-based contracts can offer a two-fold benefit for managed care executives.
Top 3 roadblocks to medication adherence and how to avoid themHere are the top three reasons for medication adherence failure and how to overcome them.
Can Amazon change the pharmacy landscape?Industry experts analyze issues of mail delivery and transparency in the prescription drug market.
Opinion: Top 2 takeaways from Asembia Specialty Pharmacy SummitThe conference raised important points about value-based contracts and the specialty pharmacy space.
Top 3 strategies employers should use to decrease healthcare costsA new Willis Towers Watson survey finds that U.S. employers have three key strategies to building cost-effective healthcare programs. 
Fourteen things Trump needs to know about opioidsAs President Trump promises fight the opioid epidemic, here are 14 things experts want him to know.
Are non-opioid therapies more desirable than opioids for chronic pain?A new study from researchers from the Minneapolis VA Health Care System has interesting findings.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.